Literature DB >> 24819932

Serum leptin levels in obese women with and without type 2 diabetes mellitus.

X Gu1, Z Chen, I El Bayoumy.   

Abstract

AIM: The role of leptin has been more clear in the endocrinology area after the discovery of its secretion from the adipose tissue. The aim of the study is to investigate the leptin levels in obese women in whom type 2 diabetes mellitus were present or absent.
METHODS: Fifty obese women with type 2 diabetes mellitus (group 1) and another 50 obese women without type 2 diabetes mellitus (group 2) were enrolled in the study. In both groups the body mass index (BMI), waist circumference, and waist-to-hip ratio were measured. Leptin, HbA1c, creatinine and the lipid profile were assessed.
RESULTS: Leptin was found to be statistically significantly lower in group 1 than in group 2 (38.79 ± 18.75 ng/ml versus 52.45 ± 16.89 ng/ml, respectively; P=0.017). In group 1, correlation of leptin was moderate with creatinine and high-density lipoprotein-cholesterol (r=0.46, p = 0.039 versus r=0.47, p=0.028, respectively), whereas triglyceride had a negative correlation (r= -0.35, p=0.047). In group 2, the only significant correlation with leptin was BMI (r=0.41, p=0.02). Leptin was also significantly lower in 24 patients with poorly controlled diabetes mellitus patients than in 26 well-controlled diabetics (35.45 ± 14.92 ng/ml versus 45.72 ± 16.69 ng/ml, respectively; p=0.029).
CONCLUSION: Since leptin is lower in obese women with diabetes than without diabetes and additionally it is even lower in the poorly controlled diabetes subgroup, we think that further studies are required to make clear the issue for lower leptin levels, whether it is a reason or an outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24819932

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  6 in total

1.  Differences in various biochemical and clinical parameters with respect to family history of Non Communicable Diseases in fourth year MBBS students of Karachi, Pakistan.

Authors:  Khalid Abdul Basit; Asher Fawwad; Muhammad Asadullah Munir; Iftikhar Ahmed Siddiqui; Sidra Siddiqui; Abdul Basit
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

2.  Adipokine Profile in Patients with Type 2 Diabetes Depends on Degree of Obesity.

Authors:  Joanna Kocot; Piotr Dziemidok; Małgorzata Kiełczykowska; Anna Hordyjewska; Grzegorz Szcześniak; Irena Musik
Journal:  Med Sci Monit       Date:  2017-10-19

3.  Body Mass Index (BMI) and Its Influence on the Cardiovascular and Operative Risk Profile in Coronary Artery Bypass Grafting Patients: Impact of Inflammation and Leptin.

Authors:  Katja Buschmann; Julius Wrobel; Ryan Chaban; Romina Rösch; Ahmed Ghazy; Alina Hanf; Katrin Schäfer; Andreas Daiber; Andres Beiras-Fernandez; Christian Friedrich Vahl
Journal:  Oxid Med Cell Longev       Date:  2020-06-23       Impact factor: 6.543

4.  Genistein treatment increases bone mass in obese, hyperglycemic mice.

Authors:  Richard M Michelin; Layla Al-Nakkash; Tom L Broderick; Jeffrey H Plochocki
Journal:  Diabetes Metab Syndr Obes       Date:  2016-03-15       Impact factor: 3.168

5.  Maternal and Fetal Lipid and Adipokine Profiles and Their Association with Obesity.

Authors:  Mario Solis-Paredes; Salvador Espino Y Sosa; Guadalupe Estrada-Gutierrez; Sonia Nava-Salazar; Veronica Ortega-Castillo; Mario Rodriguez-Bosch; Eyerahi Bravo-Flores; Aurora Espejel-Nuñez; Maricruz Tolentino-Dolores; Rubí Gaona-Estudillo; Nancy Martinez-Bautista; Otilia Perichart-Perera
Journal:  Int J Endocrinol       Date:  2016-04-12       Impact factor: 3.257

6.  Serum biomarkers of inflammation and adiposity in the LABS cohort: associations with metabolic disease and surgical outcomes.

Authors:  Robert W O'Rourke; Geoffrey S Johnson; Jonathan Q Purnell; Anita P Courcoulas; Gregory F Dakin; Luis Garcia; Marcelo Hinojosa; James E Mitchell; Alfons Pomp; Walter J Pories; Konstantinos Spaniolas; David R Flum; Abdus S Wahed; Bruce M Wolfe
Journal:  Int J Obes (Lond)       Date:  2018-05-17       Impact factor: 5.095

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.